Salud
La UE aprueba el plan de Illumina para vender el fabricante de pruebas de cáncer Grail
US gene sequencing company Illumina’s plan to sell cancer diagnostic test maker Grail got the green light from EU antitrust regulators on Friday after blocking
Nigeria se convierte en el primer país en introducir una nueva vacuna contra la meningitis
Nigeria has become the first country in the world to introduce the “revolutionary” new Men5CV vaccine against meningitis, the World Health Organisation has said. Nigeria
Moderna suspende planes para construir una planta en Kenia
Moderna said on Thursday it has put on hold its plans to build a vaccine manufacturing plant in Kenya following a post-pandemic decline in demand
La gripe aviar obliga a los productores de leche de EE.UU. a talar árboles
US dairy farmers are raising their defences to try to contain the spread of bird flu: banning visitors, felling trees to deter wild birds from
Novartis lanza una oferta pública de adquisición de MorphoSys
Novartis dijo que lanzó una oferta pública para adquirir MorphoSys, un desarrollador alemán de tratamientos contra el cáncer, por un total de 2.700 millones de euros.
Novartis recortará 680 puestos de trabajo en el desarrollo de productos
Novartis is to cut up to 680 jobs in its development organisation that helps bring its drugs to market, the Swiss drugmaker said. About 440
La inyección de Pfizer RSV alcanzó los objetivos en un estudio de adultos de alto riesgo menores de 60 años
Pfizer said Tuesday that its respiratory syncytial virus (RSV) vaccine, Abrisvo, is well tolerated and induces an immune response in high-risk adults under age 60,
La atención de género a los jóvenes es “débil”
The medical evidence underpinning gender care for adolescents is “remarkably weak” and offers little clarity on long-term outcomes, according to a state-funded NHS England study.
La inyección de Pfizer RSV alcanzó los objetivos en un estudio de adultos de alto riesgo menores de 60 años
Pfizer said Tuesday that its respiratory syncytial virus (RSV) vaccine, Abrisvo, is well tolerated and induces an immune response in high-risk adults under the age
La FDA de EE. UU. se niega nuevamente a aprobar la combinación Supernus para el Parkinson
Supernus Pharmaceuticals said the US FDA has refused to approve a drug and device combination to treat Parkinson’s disease’s movement-related symptoms, sending its shares down